Aquestive Therapeutics, Inc. AQST Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 63.5%+5.1pp | 58.3%-1.9pp | 60.3%-0.8pp | 61.1%-7.3pp | 68.4%-0.5pp | |
| Operating margin | -111.2%+48.3pp | -159.5%-30.9pp | -128.6%-9.4pp | -119.2%-43.3pp | -75.9%-22.5pp | |
| Net margin | -137.1%+51.0pp | -188.1%-29.1pp | -158.9%-11.6pp | -147.4%-47.4pp | -100%-23.3pp | |
| EBITDA margin | -110.1%+48.1pp | -158.3%-31.0pp | -127.3%-9.4pp | -117.9%-43.1pp | -74.7%-22.5pp | |
| Free cash flow margin | -88.2%+30.8pp | -119%-1.6pp | -117.4%-4.0pp | -113.3%-22.9pp | -90.4%-28.0pp | |
| Returns | ||||||
| Return on assets | -56.6%+7.4pp | -64%-13.6pp | -50.4%+11.1pp | -61.6%-14.8pp | -46.8%+8.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×+0.1× | 0.3×0.0× | 0.3×-0.1× | 0.4×-0.1× | 0.5×-0.3× | |
| Inventory turnover | 2.4×-0.6× | 3×+0.7× | 2.3×0.0× | 2.3×0.0× | 2.3×-0.5× | |
| Liquidity | ||||||
| Current ratio | 4.1×+1.0× | 3.1×-2.8× | 5.9×+2.4× | 3.5×-1.3× | 4.9×+0.2× | |
| Quick ratio | 3.8×+0.8× | 3×-2.6× | 5.6×+2.4× | 3.2×-1.3× | 4.5×+0.1× | |
| Cash ratio | 3.5×+0.9× | 2.5×-2.5× | 5×+2.4× | 2.6×-1.1× | 3.8×0.0× | |
| Leverage | ||||||
| Debt-to-assets | 0.5×+0.1× | 0.4×0.0× | 0.4×-0.3× | 0.6×+0.1× | 0.6×+0.1× | |
| Interest coverage | -5×+1.4× | -6.4×-1.4× | -5×-0.3× | -4.7×-1.0× | -3.7×-0.9× | |
| Per Share | ||||||
| Book value per share | -$0.28+11.8% | -$0.31-746% | -$0.04+94.9% | -$0.73-14.5% | -$0.64+8.0% | |
| Valuation | ||||||
| Market capitalization | $560.13M+73.5% | $788.14M+16.5% | $676.24M+112% | $318.84M+11.2% | $286.73M-11.7% | |
| Enterprise value | $513.76M+63.6% | $726.59M+19.7% | $606.83M+90.8% | $318.08M+14.4% | $277.97M-8.5% | |
| Price / sales | 11.1×+5.2× | 17.7×+2.1× | 15.6×+8.4× | 7.2×+1.9× | 5.3×-0.4× | |
| EV / sales | 10.2×+4.4× | 16.3×+2.3× | 14×+6.8× | 7.2×+2.1× | 5.1×-0.1× | |
| Free cash flow yield | -7.9%+7.3pp | -6.7%+0.8pp | -7.5%+8.2pp | -15.7%+1.4pp | -17.1%-6.0pp | |
| Earnings yield | -12.3%+4.5pp | -10.6%-0.4pp | -10.2%+10.2pp | -20.4%-1.5pp | -18.9%-5.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aquestive Therapeutics, Inc.'s profit margins?
- Aquestive Therapeutics, Inc. (AQST) runs a 63.5% gross margin and a -111.2% operating margin, with a -137.1% net margin.
- Where do Aquestive Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Aquestive Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
